Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS (G12D) A*11 T cell engager
- Development stage
- Preclinical
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KRAS (G12D) A*11 T cell engager is a bispecific antibody in discovery-stage development by Myrio Therapeutics for the treatment of KRAS G12D-mutant solid tumors, including lung, pancreatic, and colon cancers. The therapeutic is designed to recognize the KRAS G12D neoantigen peptide specifically when presented by the HLA-A*11 MHC class I molecule. By simultaneously binding this tumor-specific complex and the CD3 receptor on T cells, the engager facilitates the formation of an immunological synapse, leading to T-cell activation and the targeted destruction of cancer cells. This approach aims to overcome the challenges of targeting intracellular mutations like KRAS by utilizing the cell's natural antigen presentation machinery.
- Other names
- KRAS G12D A*11 T-cell engager
02
Targets
KRAS G12D neoantigen peptide–HLA-A*11:01 complexCD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on KRAS (G12D) A*11 T cell engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS (G12D) A*11 T cell engager.